Modulation of mitochondrial bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity

Redox Biology

Volumn 2, Issue 1, 2014, Pages 224-233

  Dott, William ^a   Mistry, Pratibha ^b   Wright, Jayne ^b   Cain, Kelvin ^c   Herbert, Karl E ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Extracellular flux analysis; Galactose; Mitochondria; Skeletal muscle toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIMYCIN A1; GALACTOSE; GLUCOSE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; BIOENERGY; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GLYCOLYSIS; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MUSCLE CELL; MYOBLAST; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RAT; RISK FACTOR; SENSITIVITY ANALYSIS; SKELETAL MUSCLE; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; CELL LINE; CULTURE TECHNIQUE; ENERGY METABOLISM; HEPG2 CELL LINE; HUMAN; METABOLISM; MUSCLE MITOCHONDRION; PROCEDURES; ADAPTATION; CELL ENERGY; CONCENTRATION (PARAMETERS); CULTURE MEDIUM; EXTRACELLULAR ACIDIFICATION RATE; IN VITRO STUDY; MITOCHONDRIAL BIOENERGETICS;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIMYCIN A; CELL CULTURE TECHNIQUES; CELL LINE; ENERGY METABOLISM; GALACTOSE; GLUCOSE; HEP G2 CELLS; HUMANS; MITOCHONDRIA, MUSCLE; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; OXYGEN CONSUMPTION; RATS;

EID: 84893181290     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.12.028     Document Type: Article

References (39)

1. Aguer C., Gambarotta D., Mailloux R.J., Moffat C., Dent R., McPherson R., Harper M.E. Galactose enhances oxidative metabolism and reveals mitochondrial dysfunction in human primary muscle cells. PloS One 2011, 6:e28536.
2. Bouitbir J., Charles A.L., Echaniz-Laguna A., Kindo M., Daussin F., Auwerx J., Piquard F., Geny B., Zoll J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur. Heart J. 2012, 33:1397-1407.
3. Brand M.D., Affourtit C., Esteves T.C., Green K., Lambert A.J., Miwa S., Pakay J.L., Parker N. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med. 2004, 37:755-767.
4. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
5. Chan K., Truong D., Shangari N., O'Brien P.J. Drug-induced mitochondrial toxicity. Expert Opin. Drug Metabol. Toxicol. 2005, 1:655-669.
6. Charaten F. Bayer decides to withdraw cholesterol drug. Br. Med. J. 2001, 323:359.
7. Davit-Spraul A., Pourci M.L., Soni T., Lemonnier A. Metabolic effects of galactose on human HepG2 hepatoblastoma cells. Metabol. Clin. Exp. 1994, 43:945-952.
8. Divakaruni A.S., Brand M.D. The regulation and physiology of mitochondrial proton leak. Physiology (Bethesda, Md.) 2011, 26:192-205.
9. Domenis R., Bisetto E., Rossi D., Comelli M., Mavelli I. Glucose-modulated mitochondria adaptation in tumor cells: a focus on ATP synthase and inhibitor factor 1. Int. J. Mol. Sci. 2012, 13:1933-1950.
10. Dranka B.P., Hill B.G., Darley-Usmar V.M. Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic. Biol. Med. 2010, 48:905-914.
11. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci.: Off. J. Soc. Toxicol. 2008, 103:335-345.
12. Dykens J.A., Marroquin L.D., Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 2007, 7:161-175.
13. Dzbek J., Korzeniewski B. Control over the contribution of the mitochondrial membrane potential (DeltaPsi) and proton gradient (DeltapH) to the protonmotive force (Deltap). In silico studies. J. Biol. Chem. 2008, 283:33232-33239.
14. Ferrick D.A., Neilson A., Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov. Today 2008, 13:268-274.
15. Gohil V.M., Sheth S.A., Nilsson R., Wojtovich A.P., Lee J.H., Perocchi F., Chen W., Clich C.B., Ayata C., Brookes P.S., Mootha V.K. Discovery and therapeutic potential of drugs that shift energy metabolism from mitochondrial respiration to glycolysis. Nat. Biotechnol. 2010, 28:249.
16. Hill B.G., Benavides G.A., Lancaster J.R., Ballinger S., Dell'Italia L., Zhang J., Darley-Usmar V.M. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol. Chem. 2012, 393(12):1485-1512.
17. Im A.R., Kim Y.H., Uddin M.R., Chae S.W., Lee H.W., Jung W.S., Kim Y.H., Kang B.J., Kim Y.S., Lee M.Y. Protection from antimycin A-induced mitochondrial dysfunction by Nelumbo nucifera seed extracts. Environ. Toxicol. Pharmacol. 2013, 36:19-29.
18. Itagaki M., Takaguri A., Kano S., Kaneta S., Ichihara K., Satoh K. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J. Pharmacol. Sci. 2009, 109:94-101.
19. Kase E.T., Nikolic N., Bakke S.S., Bogen K.K., Aas V., Thoresen G.H., Rustan A.C. Remodeling of oxidative energy metabolism by galactose improves glucose handling and metabolic switching in human skeletal muscle cells. PloS One 2013, 8:e59972.
20. Kaufmann P., Torok M., Zahno A., Waldhauser K.M., Brecht K., Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell. Mol. Life Sci.: CMLS 2006, 63:2415-2425.
21. Ma X., Jin M., Cai Y., Xia H., Long K., Liu J., Yu Q., Yuan J. Mitochondrial electron transport chain complex III is required for antimycin A to inhibit autophagy. Chem. Biol. 2011, 18:1474-1481.
22. Marroquin L.D., Hynes J., Dykens J.A., Jamieson J.D., Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci.: Off. J. Soc. Toxicol. 2007, 97:539-547.
23. Neustadt J., Pieczenik S.R. Medication-induced mitochondrial damage and disease. Mol. Nutr. Food Res. 2008, 52:780-788.
24. Owczarek J., Jasinska M., Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol. Rep.: PR 2005, 57:23-34.
25. Palmfeldt J., Vang S., Stenbroen V., Pedersen C.B., Christensen J.H., Bross P., Gregersen N. Mitochondrial proteomics on human fibroblasts for identification of metabolic imbalance and cellular stress. Proteome Sci. 2009, 7:20. (5956-7-20).
26. Pereira C.V., Moreira A.C., Pereira S.P., Machado N.G., Carvalho F.S., Sardao V.A., Oliveira P.J. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety?. Curr. Drug Saf. 2009, 4:34-54.
27. Rana P., Nadanaciva S., Will Y. Mitochondrial membrane potential measurement of H9c2 cells grown in high-glucose and galactose-containing media does not provide additional predictivity towards mitochondrial assessment. Toxicol. in Vitro: Int. J. Publ. Assoc. BIBRA 2011, 25:580-587.
28. Reily C., Mitchell T., Chacko B.K., Benavides G., Murphy M.P., Darley-Usmar V. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol. 2013, 1:86-93.
29. Reitzer L.J., Wice B.M., Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 1979, 254:2669-2676.
30. Robinson B.H., Petrova-Benedict R., Buncic J.R., Wallace D.C. Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochem. Med. Metab. Biol. 1992, 48:122-126.
31. Robinson G.L., Dinsdale D., Macfarlane M., Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene 2012, 31:4996-5006.
32. Rolfe D.F., Newman J.M., Buckingham J.A., Clark M.G., Brand M.D. Contribution of mitochondrial proton leak to respiration rate in working skeletal muscle and liver and to SMR. Am. J. Physiol. 1999, 276:C692-C699.
33. Rossignol R., Gilkerson R., Aggeler R., Yamagata K., Remington S.J., Capaldi R.A. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 2004, 64:985-993.
34. Rusyniak D.E., Tandy S.L., Hekmatyar S.K., Mills E., Smith D.J., Bansal N., MacLellan D., Harper M.E., Sprague J.E. The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine-mediated skeletal muscle hyperthermia and rhabdomyolysis. J. Pharmacol. Exp. Ther. 2005, 313:629-639.
35. Scruggs E.R., Dirks Naylor A.J. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2008, 82:83-88.
36. Serviddio G., Sastre J. Measurement of mitochondrial membrane potential and proton leak. Methods Mol. Biol. (Clifton, N.J.) 2010, 594:107-121.
37. R., Swiss, Y., Will, Assessment of mitochondrial toxicity in HepG2 cells cultured in high-glucose- or galactose-containing media, Current Protocols in Toxicology/Editorial Board, Mahin D. Maines et al. (Editor-in-Chief), Unit2.20, 2011 (Chapter 2).
38. Wagner A., Marc A., Engasser J.M., Einsele A. Growth and metabolism of human tumor kidney cells on galactose and glucose. Cytotechnology 1991, 7:7-13.
39. Wamelink M.M., Struys E.A., Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. J. Inherit. Metab. Dis. 2008, 31:703-717.